Sulzberger Capital Advisors Inc. Takes $312,000 Position in Pfizer Inc. (NYSE:PFE)

Sulzberger Capital Advisors Inc. acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 11,770 shares of the biopharmaceutical company's stock, valued at approximately $312,000.

A number of other hedge funds also recently modified their holdings of the business. Passumpsic Savings Bank grew its holdings in Pfizer by 8.4% during the 3rd quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company's stock worth $743,000 after acquiring an additional 1,998 shares during the period. Virtu Financial LLC bought a new position in Pfizer during the third quarter valued at about $1,499,000. Westside Investment Management Inc. increased its stake in shares of Pfizer by 7.7% during the 3rd quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company's stock worth $404,000 after purchasing an additional 1,004 shares during the last quarter. Diamant Asset Management Inc. raised its stake in shares of Pfizer by 8.4% in the third quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company's stock valued at $246,000 after buying an additional 660 shares during the period. Finally, Morse Asset Management Inc purchased a new stake in Pfizer during the third quarter valued at about $2,649,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group raised their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday. Finally, The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, five have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $29.64.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by company insiders.

Pfizer Price Performance

PFE traded up $0.26 during trading on Friday, reaching $24.19. 41,672,273 shares of the company traded hands, compared to its average volume of 40,568,476. The company has a market cap of $137.19 billion, a P/E ratio of 17.16, a PEG ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a fifty day simple moving average of $24.34 and a 200 day simple moving average of $25.78.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue for the quarter was down 7.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.82 earnings per share. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.11%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.